OBJECTIVES: Due to being immunocompromised, cancer patients are at higher risk of contracting COVID-19, as well as severe complications as a result. The means to report COVID-19 symptoms quickly and accurately to a clinician is critical so they can receive immediate care to reduce long term impacts and reduce risk of potential death. The Obvio-19 app was developed to issue users a series of once daily questions regarding their health, symptomology, and COVID-19 exposure opportunities such that potential COVID-19 infection could be quickly identified. In the ONCOVID Study, patients’ sentiment regarding ease of use of the app is assessed.

METHODS: Thirty-three (n=33) cancer patients were recruited from Saint Joseph Hospital in Paris and asked to utilize the Obvio-19 app over a six-month period, no patients with blood cancers were included. The purpose of this study was to evaluate cancer patient user experience with Obvio-19 application including ease of use and sentiments regarding its use for reporting. Of thirty-three patients, none contracted COVID-19 and sixteen (n=16) were able to complete the OBVIONCO survey after 6 months of use regarding their experience.

RESULTS: When asked to rate “Ease of use of the Obvio-19 app” from 1 to 5 with 5 being “very easy” and 1 being “very difficult”, 88% (n=14) selected “5 – very easy” and the remaining 12% (n=2) selected “4”. Additionally, 82% (n=13) communicated that they felt completing the questionnaire in an electronic application is easier that a paper form. 88% (n=14) felt the there was an appropriate number of questions asked each day and all patients (n=16) were able to complete the daily process in less than 2 minutes.

CONCLUSIONS: This study demonstrates how electronic application-based monitoring provides less burden on cancer patients monitored and treated from home and reduces need for clinic visits and potential unnecessary exposure to COVID-19.